Vaxcyte Inc
PCVX
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
100.9% downsideOvervalued by 100.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.42 Billion |
|---|---|
| Enterprise Value | $7.39 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.63 |
| Beta | 1.3 |
| Outstanding Shares | 139,506,680 |
Return
| Return on Equity | -31.59% |
|---|---|
| Return on Assets | -28.27% |
| Return on Invested Capital | -32.24% |
Valuation & Multiples
| P/E Ratio | -7.58 |
|---|---|
| PEG | -5.93 |
| Price to Sales | - |
| Price to Book Ratio | 2.23 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.38 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.6467▼ 0.90% |
|---|---|
| Total Calls | 1,041,535▲ 661.36% |
| Total Puts | 1,715,100▲ 657.22% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 119.43%▲ 11.08% |
|---|---|
| Total Invested | $9.44B▲ 38.58% |
| Investors Holding | 349▲ 46.00% |
ESG Score
No data
About Vaxcyte Inc
14,000 employees
CEO: Grant Pickering Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-fre...
Relevant Senate Committees
This powerful committee controls taxation, trade, and entitlement spending (e.g., Medicare). Its decisions on corporate tax policy, R&D credits, and Medicare pricing for vaccines would directly and significantly impact Vaxcyte's profitability, market access, and overall valuation.
This committee directly allocates federal spending. Its subcommittees determine funding for agencies like NIH, CDC, and potentially the VA, which are crucial sources for research grants, public health initiatives, and vaccine procurement, directly impacting Vaxcyte's potential funding and market.
This committee directly regulates the FDA and NIH. FDA approval is paramount for Vaxcyte's products, and NIH funding is vital for biomedical research. This committee is central to the regulatory and funding environment for the pharmaceutical and biotech sectors.